The question of why two pharmacologically distinct drug classes — NMDA receptor antagonists like ketamine and serotonergic psychedelics like psilocybin and LSD — both produce antidepressant effects within hours has puzzled neuroscience for over a decade. A new multimodal study in Molecular Psychiatry now offers a compelling mechanistic bridge: convergent neuroimmune signaling, centered on interleukin and B-cell pathways, may be the shared downstream architecture that makes rapid antidepressant response possible regardless of the upstream receptor engaged.
The research employed an unusually rich methodological stack, integrating cerebrospinal fluid proteomics from healthy volunteers receiving intravenous ketamine, transcriptomic data from induced pluripotent stem cell (iPSC)-derived neurons exposed to ketamine, its active metabolite (2R,6R)-hydroxynorketamine, LSD, and psilocybin, along with magnetoencephalography (MEG), plasma cytokine profiling, and whole-blood transcriptomics from treatment-resistant depression (TRD) participants. Across these layers, two immune proteins — interleukin-15 (IL-15) and monocyte chemoattractant protein-1 (MCP-1) — emerged as convergent regulatory hubs. Notably, ketamine responders showed reduced baseline IL-15 and elevated B-cell signaling that reversed following treatment. Plasma IL-7, a primary B-cell driver, correlated with baseline MEG gamma power across all participants at brain-wide significance.
This work carries meaningful implications for the treatment-resistant depression landscape. The identification of immune-neural crosstalk as a shared antidepressant mechanism challenges the prevailing neurotransmitter-centric framework and raises the possibility that baseline immune signatures could serve as predictive biomarkers for treatment response — an area of enormous unmet clinical need. The iPSC approach allows human-relevant cellular modeling without requiring brain tissue, though it cannot fully replicate in vivo synaptic complexity. The TRD cohort sizes are modest, and replication in larger, independent samples is essential. Nevertheless, the cross-platform convergence of immune signals across CSF, blood, and neural oscillation data gives this finding unusual mechanistic coherence — marking it as more than incremental progress in understanding why fast-acting antidepressants work.